Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis;Sensibilidad de la escala ampliada del estado de discapacidad (EDSS) a la progresión de la enfermedad y la intervención terapéutica en las formas progresivas de la esclerosis múltiple

Revista de Neurologia

Volumn 51, Issue 6, 2010, Pages 321-329

  Cadavid, Diego ^a   Tang, Yongqiang ^a   O'Neill, Gilmore ^a  

^a BIOGEN   (United States)

Author keywords

Disability; EDSS; Effect size; Multiple sclerosis; PPMS; SPMS

Indexed keywords

PLACEBO;

9 HOLE PEG; ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; HUMAN; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; OUTCOME ASSESSMENT; PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS; RECURRENT DISEASE; SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS; TASK PERFORMANCE; TIMED 25 FOOT WALK; TREATMENT OUTCOME;

EID: 78649835481     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5106.2010390     Document Type: Article

References (40)

1. Kurtzke JF. A new scale for evaluating disability in multiple sclerosis. Neurology 1955; 5: 580-3.
2. Kurtzke JF. Further notes on disability evaluation in multiple sclerosis, with scale modifications. Neurology 1965; 15: 654-61.
3. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-52.
4. Kurtzke JF. Origin of DSS: to present the plan. Mult Scler 2007; 13: 120-3.
5. Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14-24.
6. Wolinsky JS. The PROMiSe trial: baseline data review and progress report. Mult Scler 2004; 10 (Suppl 1): S65-72.
7. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-71.
8. Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004; 63: 1779-87.
9. Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F. Final analysis of the European multicenter trial on IFNbeta-1b in secondary- progressive MS. Neurology 2001; 57: 1969-75.
10. Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001; 56: 1505-13.
11. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-504.
12. European Study Group on Interferon Beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7.
13. Hobart J, Freeman J, Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 2000; 123 (Pt 5): 1027-40.
14. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997; 42: 379-82.
15. Goodkin DE, Priore RL, Wende KE, Campion M, Bourdette DN, Herndon RM, et al. Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler 1998; 4: 480-6.
16. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122 (Pt 5): 871-82.
17. Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol 2000; 57: 1319-24.
18. Kragt JJ, Thompson AJ, Montalban X, Tintoré M, Río J, Polman CH, et al. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology 2008; 70 (Pt 2): 1084-91.
19. Bosma LV, Kragt JJ, Brieva L, Khaleeli Z, Montalban X, Polman CH, et al. Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components? Mult Scler 2010; 16: 862-7.
20. Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, et al. Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler 2009; 15: 984-97.
21. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-87.
22. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak AJ, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001; 58: 961-7.
23. Fischer J, Jak AJ, Kniker JE, Rudick R, Cutter G. Multiple Sclerosis Functional Composite (MSFC) administration and scoring manual. 2001. URL: http://www.nationalmssociety.org/for-professionals/researchers/ clinical-study-measures/msfc/index.aspx.
24. Cohen J. Statistical power analysis for the behavioral sciences. 2 ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
25. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol 2010; 67: 64-70.
26. Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004; 57: 898-910.
27. Hoogervorst EL, Kalkers NF, Cutter GR, Uitdehaag BM, Polman CH. The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult Scler 2004; 10: 55-60.
28. Kragt JJ, Van der Linden FA, Nielsen JM, Uitdehaag BM, Polman CH. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler 2006; 12: 594-8.
29. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-11.
30. Paltamaa J, Sarasoja T, Leskinen E, Wikstrom J, Malkia E. Measures of physical functioning predict self-reported performance in self-care, mobility, and domestic life in ambulatory persons with multiple sclerosis. Arch Phys Med Rehabil 2007; 88: 1649-57.
31. Paltamaa J, Sarasoja T, Leskinen E, Wikstrom J, Malkia E. Measuring deterioration in international classification of functioning domains of people with multiple sclerosis who are ambulatory. Phys Ther 2008; 88: 176-90.
32. Paltamaa J, Sarasoja T, Wikstrom J, Malkia E. Physical functioning in multiple sclerosis: a population-based study in central Finland. J Rehabil Med 2006; 38: 339-45.
33. Paltamaa J, West H, Sarasoja T, Wikstrom J, Malkia E. Reliability of physical functioning measures in ambulatory subjects with MS. Physiother Res Int 2005; 10: 93-109.
34. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ 1993; 2: 217-27.
35. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc 2006; 54: 743-9.
36. Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD. Quantitative functional measures in MS: what is a reliable change? Neurology 2002; 58: 1294-6.
37. Hoogervorst EL, Kalkers NF, Van Winsen LML, Uitdehaag BM, Polman CH. Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis. Mult Scler 2001; 7: 335-9.
38. Contelloe L, Hutchinson M. Is a 20% change in MSFC components clinically meaningful? Mult Scler 2007; 13: 1076.
39. Costelloe L, O'Rourke K, Kearney H, McGuigan C, Gribbin L, Duggan M, et al. The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical). J Neurol Neurosurg Psychiatry 2007; 78: 841-4.
40. Schwid SR, Goodman AD, Mattson DH, Mihai C, Donohoe KM, Petrie MD, et al. The measurement of ambulatory impairment in multiple sclerosis. Neurology 1997; 49: 1419-24.